Related Experiment Video
Updated: Jul 11, 2025
10:19
Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
Published on: May 12, 2023
1.3K
T-Cell Engaging Antibodies in Diffuse Large B Cell Lymphoma-An Update
Shalini Balendran1, Constantine Tam1, Matthew Ku2
1Alfred Health, Melbourne, VIC 3004, Australia.
Journal of Clinical Medicine
|November 14, 2023
Summary
Novel T-cell engaging antibodies (TCEAbs) show promise for relapsed/refractory diffuse large B cell lymphoma (DLBCL). These therapies harness the immune system to fight cancer, with ongoing research into their effectiveness and management of side effects.
Area of Science:
- Oncology
- Immunology
Background:
- Diffuse large B cell lymphoma (DLBCL) presents challenges in the relapsed/refractory (R/R) setting.
- Novel cellular immunotherapies are emerging as significant treatment options.
Purpose of the Study:
- To review the development and mechanism of action of T-cell engaging antibodies (TCEAbs) in DLBCL treatment.
- To examine clinical trial data, adverse event management, and resistance mechanisms of TCEAbs.
Main Methods:
- Review of published clinical trial data on TCEAbs for R/R DLBCL.
- Analysis of TCEAb mechanisms, efficacy, and safety profiles.
Main Results:
- TCEAbs demonstrate promising effectiveness in R/R DLBCL, achieving complete remissions in heavily pretreated patients.
- Established therapies like blinatumomab paved the way for novel TCEAb development.
Conclusions:
- TCEAbs represent a significant advancement in treating R/R DLBCL.
- Appropriate recognition and management of unique toxicities like cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity (ICANS) are crucial for successful treatment.
Related Concept Videos
01:24B Cell Activation and Differentiation
1.7K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.7K
01:27Tumor Immunotherapy
533
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
533
01:22T Cell Activation and Clonal Selection
753
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
753